Previous 10 | Next 10 |
Yumanity Therapeutics (YMTX): Q1 GAAP EPS of -$0.85 misses by $0.04.Revenue of $3.53M beats by $3.03M.Press Release For further details see: Yumanity Therapeutics EPS misses by $0.04, beats on revenue
Demonstrated lead program YMTX-7739 inhibits novel target in healthy volunteers at levels consistent with improved motor function in an animal model of Parkinson’s disease Initiated dosing in Phase 1b portion of multi-dose trial of YMTX-7739 in patients with Parkinson...
BOSTON, May 12, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that Richard Peters, M.D., Ph.D., Pre...
BOSTON, May 04, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a biopharmaceutical company focused on the development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that the Company will host a virtual R&D Day on Monday, May 17...
BOSTON, April 28, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that Richard Peters, M.D., Ph.D., P...
BOSTON, April 22, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today reported that its lead product candidate, YTX...
BOSTON, April 13, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a biopharmaceutical company focused on the development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced the appointment of Ajay Verma, M.D., Ph.D., as Executive Vice Pr...
Yumanity Therapeutics (YMTX) announces results of a study that demonstrate in vivo efficacy, including increased median overall survival, of YTX-7739 in a mouse model for glioblastoma multiforme ((GBM)).YTX-7739 is currently in clinical development by YMTX as a potential treatment for Parkins...
YTX-7739 demonstrates efficacy, including increased median overall survival, both as a single agent and in combination with temozolomide, the standard-of-care for GBM Shared therapeutic target with Parkinson’s disease expands potential utility of YTX-7739 to non-neuro...
Yumanity Therapeutics (YMTX): FY GAAP EPS of -$21.57.Revenue of $6.9MShares +1.43%.Press Release For further details see: Yumanity Therapeutics reports FY results